Prenetics Global Ltd
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
The business works in principle: IM8 demonstrably sells, the gross margin carries, and with $121.0 million of equity, roughly $106 million in cash and securities as of March 31, 2026 and no debt, the balance sheet is not in danger — there is no documented threat to the substance of the company that would justify red. What is open is a decidedly weighty operational question: in its current shape Prenetics has not produced a single year of operating profit, and the operating loss grew in 2025 even as revenue rose sixfold. On top of that, the most important growth metric is defined by the company itself and verified by no third party, which makes progress harder to check than the headlines suggest. Anyone investing is betting that the marketing machine will one day cost less than the revenue it produces. That remains unproven. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Prenetics is the rare case where the growth story checks out and caution is still warranted. Revenue genuinely climbed from $6.2 million to $92.4 million in two years and the gross margin reached 65 percent in the first quarter of 2026 — yet the operating loss grew with it, to $44.5 million in 2025, and the friendlier net loss of $40.0 million owes itself to a one-off warrant exchange worth $36.7 million. The metric everyone quotes is an extrapolation: ARR is, by the company's own definition, one month of revenue times twelve, and nobody outside the company has verified those numbers. Add 67.72 percent of the votes in one pair of hands against a 10.19 percent capital stake, a loss-making bitcoin detour and a reporting status without quarterly filings. Anyone buying here gets a real brand with real revenue growth — and at the same time relies on figures the company defines itself. Not investment advice.
Growth and demand
The growth is real and cannot be argued away: revenue from continuing operations rose from $6.2 million in 2023 to $15.9 million in 2024 and $92.4 million in 2025, with another $35.95 million in the first quarter of 2026. The gross margin improved from 19.1 percent in 2023 to 52.8 percent in 2025 and 65 percent in the quarter. IM8 shipped to more than 30 countries in 2025 and to 43 by the end of the first quarter of 2026.
Earnings power
The operations earn nothing. The operating loss grew alongside revenue: $38.4 million in 2023, $36.3 million in 2024 and $44.5 million in 2025, plus $8.9 million in the first quarter of 2026. Cash burn stayed heavy too, at $21.8 million in 2025 and $12.1 million in the first quarter of 2026 alone. In its current shape this company has never delivered a year of operating profit.
Quality of earnings and metrics
The 2025 net loss of $40.0 million only looks better than the operating loss of $44.5 million because a one-off warrant exchange added $36.7 million. The headline metric ARR is, by the annual report's own footnote, one month of revenue multiplied by twelve, and Prenetics states that its metrics have not been independently verified by any third party. Our in-house balance-sheet warning screen, the Beneish M-Score, listed the stock on July 25, 2026.
Balance sheet and funding
For a loss-making company the balance sheet is comfortable: $56.0 million of cash and $50.0 million of financial assets as of March 31, 2026, plus $41.3 million from the bitcoin sale, $121.0 million of equity and, by the company's own account, no debt. The General Catalyst facility of up to $1 billion (July 14, 2026) dilutes nobody — but it sits on the balance sheet as a financial liability, and its price lands as interest expense below operating income.
Control and capital allocation
Founder Danny Yeung holds 10.19 percent of the capital and 67.72 percent of the voting power (annual report 20-F for 2025). As a controlled company and foreign private issuer, Prenetics is exempt from quarterly reports (10-Q), current reports (8-K) and several Nasdaq governance requirements; the board has four members, two of them independent. The bitcoin detour between June and December 2025 cost around $13 million and shows how quickly capital changes direction here.
Valuation
As of July 25, 2026 the market capitalization stood at $330.1 million, or roughly 2.7 times trailing twelve-month revenue of $120.1 million. For a company that has grown revenue fifteenfold in two years that is not excessive — but the price already assumes the company's own guidance holds, namely $210 million to $220 million of IM8 revenue in 2026. A price-to-earnings ratio does not exist for want of earnings.
Worth Noting
Prenetics reached our research list through the daily Reddit hype scan: 2 mentions at a market capitalization of $330.1 million, as of July 25, 2026. On the same day the stock appeared on nine momentum and growth screens of our in-house stock scanner — and simultaneously on the risk screen named Beneish M-Score, a balance-sheet warning indicator. All of these lists are recalculated daily.
All annual figures come from the 20-F annual report for 2025 (filed April 30, 2026) and refer to continuing operations; the 2023 and 2024 figures were restated under IFRS 5 after the disposals of ACT Genomics, the European logistics business and the Insighta stake. Quarterly figures as of March 31, 2026 are taken from the 6-K interim disclosure filed June 10, 2026.
Do not confuse the terms: at Prenetics, ARR is not an audited revenue measure but monthly revenue multiplied by twelve. IM8 generated $60.1 million of revenue in the full year 2025 while the $120 million ARR figure was in circulation. Valuation figures are dated and meant to be evergreen; daily share prices are not a reason to buy.
Stock Watch
This analysis is as of August 29, 2026. Stock Watch will tell you what's changed at PRE since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 10.70 $ to 26.30 $ · Last price: 24.20 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Packaged Foods
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Prenetics Global Ltd PRE | 0.4 | – | 0.1 | 57.8 | – | 201.7 | 125.7 |
| JBS N.V. JBS | 39.9 | 11.7 | 6.2 | 11.8 | 2.5 | 13.0 | -16.1 |
| Kraft Heinz Co KHC | 29.1 | – | 13.1 | 33.5 | 20.7 | -3.5 | 2.7 |
| General Mills Inc GIS | 19.9 | 9.2 | 21.6 | 33.7 | 19.2 | -1.9 | -20.8 |
| McCormick & Company Incorporated MKC-V | 13.8 | 8.6 | 13.4 | 38.9 | 17.4 | 1.7 | -18.7 |
| McCormick & Company Incorporated MKC | 13.5 | 8.9 | 13.1 | 38.9 | 17.4 | 1.7 | -23.2 |
| The J. M. Smucker Company SJM | 12.8 | – | 14.8 | 38.0 | 18.5 | 3.7 | 22.5 |
| Hormel Foods Corporation HRL | 11.6 | 28.1 | 15.5 | 15.7 | 11.1 | 1.6 | -12.2 |
| Darling Ingredients Inc DAR | 10.7 | 48.5 | 9.6 | 26.3 | 8.1 | 7.4 | 100.8 |
| Median of companies shown | 13.5 | 10.4 | 13.1 | 33.7 | 17.4 | 1.7 | -12.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2013 | 5,590 | 833 | 664 | 11.86 | 827 | 6,766 | 23,038 |
| 2014 | 6,477 | 1,334 | 1,055 | – | 853 | 7,104 | 22,270 |
| 2015 | 5,477 | 642 | 104 | – | 319 | 6,903 | 21,406 |
| 2019 | 9 | -21 | -20 | -2.72 | -2 | 17 | 30 |
| 2020 | 65 | -1 | -2 | -0.26 | -3 | 31 | 79 |
| 2021 | 13 | -57 | -174 | -47.04 | 13 | -401 | 149 |
| 2022 | 13 | -66 | -190 | -37.57 | 15 | 237 | 312 |
| 2023 | 22 | -52 | -63 | -5.58 | -14 | 206 | 254 |
| 2024 | 31 | -48 | -46 | -3.64 | -29 | 170 | 214 |
| 2025 | 92 | -38 | -38 | -2.68 | -22 | 175 | 204 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.06 | – | 11 | 93.20 | -155.80 | – | – |
| 2025: Q1 | -1.06 | – | 11 | 63.50 | -155.80 | -4 | -4 |
| 2025: Q2 | -0.80 | – | 18 | 197.50 | -70.20 | -5 | -5 |
| 2025: Q3 | -0.48 | – | 24 | 202.80 | -31.40 | – | – |
| 2025: Q4 | -1.82 | – | 37 | 248.60 | -76.90 | -22 | -22 |
| 2026: Q1 | -1.50 | – | 36 | 242.80 | -64.30 | -12 | -12 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Growth
Breakout & Setup
Momentum & Trend
- 21-EMA Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Mark Minervini: Trend Criteria — 1 Month
- Stan Weinstein: Stage 2
Research
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.88 | -2.88 – -2.88 | 224 | -113.7% | 1 |
| 12/31/2027 | -2.68 | -4.41 – -0.94 | 403 | 7.1% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
AI classification
AI Rating
Prenetics verkauft keine KI, sondern setzt sie im eigenen Betrieb ein: Der Jahresbericht 20-F für 2025 beschreibt generative KI als Produktionsmittel für Werbemittel und bezeichnet das Betriebsmodell selbst als KI-getrieben.
View the full file — quotes, sources, reviewed filings
„We are a consumer health company advancing human health and longevity through science-backed products, global brand partnerships, and AI-driven operations."
Wir sind ein Verbrauchergesundheits-Unternehmen, das menschliche Gesundheit und Langlebigkeit durch wissenschaftlich belegte Produkte, globale Markenpartnerschaften und KI-getriebene Abläufe voranbringt.
20-F · 2026-04-30 · View SEC filing
„We utilize generative AI for advertising production—video, imagery, and copy—at scale, speed, and cost levels that would be impossible with traditional production methods."
Wir nutzen generative KI für die Werbemittel-Produktion — Video, Bild und Text — in einem Umfang, einem Tempo und zu Kosten, die mit herkoemmlichen Produktionsmethoden unmöglich wären.
20-F · 2026-04-30 · View SEC filing
Filings Reviewed: 20-F 2026-04-30 · 20-F/A 2026-07-02 · 6-K 2026-06-10 · 6-K 2026-07-14
Rated on July 26, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 91.4%
- More than 10% revenue growth is expected for the coming year 57.3%
- Share count grows by less than 3% a year 40.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 177.9%
- Gross margin at 40% or higher and without meaningful erosion 52.8%
- Goodwill from acquisitions does not grow faster than revenue 0.7%
- Net debt below twice EBITDA 59 m net cash
- Operating cash flow covers the profits of the last three years 82 m
- Return on capital at 15% or higher, or up versus two years ago -21.7%
- Insiders hold at least 10% or are net buyers 13.8%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -29.0%
- Exp. sales growth 3Y > 5% 108.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 108.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% -29.3%
- ROCE > 15% -21.7%
- Expected return > 10% 97.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Leogrande Hudson Blake | Director | Other | 2,000 | 0.00 | – |
| Aug 25, 2026 | Rosin Brian J | CFO of IM8 (US) LLC | Buy | 5,100 | 22.80 | 116,280 |
| Aug 24, 2026 | Rosin Brian J | CFO of IM8 (US) LLC | Buy | 18,000 | 21.19 | 381,420 |
| Aug 24, 2026 | Yeung Danny Sheng Wu | Chief Executive Officer | Buy | 11,181 | 21.40 | 239,273 |
| Aug 24, 2026 | Yeung Danny Sheng Wu | Chief Executive Officer | Buy | 6,000 | 20.90 | 125,400 |
| Aug 21, 2026 | Lo Hoi Chun | Chief Financial Officer | Other | 45,815 | 0.00 | – |
| Aug 21, 2026 | Lo Hoi Chun | Chief Financial Officer | Other | 32,736 | 0.0001 | 3 |
| Aug 20, 2026 | Yeung Danny Sheng Wu | Chief Executive Officer | Buy | 7,500 | 18.31 | 137,325 |
| Aug 20, 2026 | Yeung Danny Sheng Wu | Chief Executive Officer | Other | 49,912 | 0.00 | – |
| Aug 20, 2026 | Yeung Danny Sheng Wu | Chief Executive Officer | Other | 53,953 | 0.0001 | 5 |
The company
About the Company
Prenetics Global Limited ist ein Unternehmen für Consumer Health Sciences in den USA und Hongkong. Das Unternehmen konzentriert sich auf die Förderung der menschlichen Gesundheit und Langlebigkeit durch wissenschaftlich fundierte Produkte unter der Marke IM8.
- Employees
- 98
- Headquarters
- Quarry Bay, Hong Kong
- Address
- Unit 703-706, K11 Atelier King’s Road, Quarry Bay, Hong Kong
- Phone
- 852 2210 9588
- Website
- prenetics.com
- IPO Date
- 05/18/2022
- ISIN
- KYG722451229
- Stock Split
- 1:15 on 11/14/2023
- Stock Split
- 129:100 on 05/18/2022
Management
| Name | Title | Birth Year |
|---|---|---|
| Sheng Wu Yeung | Co-Founder, Chairperson & CEO | 1979 |
| Samantha Kwok | Chief of Staff & VP of People & Operations | – |
| Brian Chae | General Counsel | – |
| Senthil Kumar Sundaram M.D. | Chief Clinical Officer | 1974 |
| Brian J. Rosin | Chief Financial Officer of U.S. | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.